Apotex Health Corp. has priced its upsized initial public offering at $24.00 per common share, targeting gross proceeds of $1,300,000,080. The company filed its final base PREP prospectus and entered into an underwriting agreement to facilitate the offering, which consists of 54,166,670 common shares. This pricing represents the top end of the previously indicated range of $20.00 to $24.00, securing the maximum anticipated capital for the Canadian-based global health company.

Offering Structure

The offering comprises a treasury offering by Apotex of 35,416,666 common shares, expected to generate gross proceeds of $849,999,984, and a secondary offering by certain shareholders of 18,750,004 common shares, expected to generate gross proceeds of $450,000,096. The Selling Shareholders have granted the underwriters an over-allotment option to purchase up to an additional 8,125,000 common shares at the offering price. This option is exercisable at any time, in whole or in part, until 30 days after the closing date to cover over-allotments and for market stabilization purposes.

Trading and Closing Details

The common shares are scheduled to begin trading on the Toronto Stock Exchange (TSX) on an "if, as and when issued" basis on June 10, 2026, under the symbol "APTX." The TSX has conditionally approved the listing, subject to fulfilling customary requirements. The closing of the offering is expected to occur on or about June 16, 2026, subject to customary closing conditions.

Underwriters and Legal Counsel

A syndicate of underwriters is managing the offering, led by RBC Capital Markets, TD Securities Inc., and Scotiabank as co-lead managers, joint global coordinators, and joint lead bookrunners. Joint bookrunners include BMO Capital Markets and Jefferies Securities, Inc., while co-managers comprise CIBC Capital Markets, ATB Cormark Capital Markets, Desjardins Capital Markets, National Bank Capital Markets, MUFG, Raymond James, Bloom Burton Securities Inc., Canaccord Genuity Corp., Stifel, and Paradigm Capital Inc. Goodmans LLP is acting as Canadian legal counsel to Apotex, with Stikeman Elliott LLP advising the underwriters. Kirkland & Ellis LLP is serving as US legal counsel to Apotex, and Skadden, Arps, Slate, Meagher & Flom LLP is acting as US legal counsel to the underwriters.

Prospectus Availability

The Final Prospectus contains important information relating to the company, the common shares, and the offering. A supplemented PREP prospectus containing pricing information will be available on or about June 10, 2026. Copies of the Final Prospectus are accessible on SEDAR+ at www.sedarplus.com . Electronic or paper copies may also be obtained without charge from the lead underwriters, including RBC Dominion Securities Inc., TD Securities Inc., and Scotia Capital Inc.